New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT05199753

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 20 times

Summary

This study tested a new drug called LM-108, alone or with an anti-PD-1 antibody, in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Early results focus on controlling tumor growth, not curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Victoria, VIC 3004, Australia

  • Blacktown Hospital

    Sydney, New South Wales, NSW 2148, Australia

  • Cabrini Health Limited

    Malvern, Victoria, VIC 3144, Australia

  • ICON Cancer Centre

    South Brisbane, Queensland, QLD 4101, Australia

  • One Clinical Research Pty Ltd.

    Nedlands, Western Australia, WA 6009, Australia

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, QLD 4575, Australia

Conditions

Explore the condition pages connected to this study.